Ponatinib acts against the most resistant types of chronic myeloid leukemia
Wednesday, November 28, 2012 - 20:30
in Health & Medicine
Phase I trial shows third-generation drug helps patients after other treatments fail.
Updated by artificial intelligence Sat, 3 Jan 2026, 15:40:35 UTC Learn more
- Tell your friends
- Get science news via